Investors / United States / Brace Pharma Capital
Brace Pharma Capital
Corporate VC · Atlanta, GA, United States · North America
Brace Pharma Capital is a strategic investment firm formed by EMS S/A, described as the largest pharmaceutical company in Brazil, together with high net worth biotech investors. It invests in innovative therapies for diseases with a high degree of unmet medical need and insufficient treatment options.
Invests inHealthcare & Biotech
In its own wordsbiotechpharmaceuticalsorphan drugstherapeuticsclinical stagelife sciences
Your fit with Brace Pharma Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBrace Pharma Capital lists 9 checked portfolio companies on its own site. Its largest themes are Healthcare & Biotech (78%), Enterprise Software (11%) and Media & Entertainment (11%). 60% of its companies are based in United States. It invests most often alongside Aisling Capital, Lumira Ventures and Osage University Partners.
No funding round on record names Brace Pharma Capital yet, so the figures come from its portfolio page.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 19th | 9 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 93th | 78% in its largest sector |
| Reach | 58th | 3 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers889%
- No longer answers00%
- Points to another company111%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 78% | 15% |
| Enterprise Software | 11% | 8% |
| Media & Entertainment | 11% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare Brace Pharma Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
9 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Antiva Biosciences is developing a novel topical therapeutic for the treatment of oncogenic human papillomavirus infections and pre-cancerous cervical lesions | Healthcare & Biotech | Portfolio page | ||
| Avidity Biosciences is developing RNA therapeutics for rare muscle diseases | Healthcare & Biotech | Portfolio page | ||
Enterprise SoftwareMedia & Entertainment | Portfolio page | |||
| F2G develops therapeutics for rare fungal infections | Healthcare & Biotech | Portfolio page | ||
| Gliknik discovers and develops drugs for immune disorders, including autoimmune diseases and cancers. | Healthcare & Biotech | Portfolio page | ||
| Precision BioSciences is using its novel ARCUS genome-editing technology to develop a new class of medicines designed to overcome and potentially cure hard-to-treat conditions, including rare genetic diseases. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Vero Biotech develops and commercializes inhaled nitric oxide delivery systems | Healthcare & Biotech | Portfolio page | ||
| Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing novel, multifunctional biotherapeutics for difficult-to-treat diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- bracepharma.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Companies checked
- 9
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Brace Pharma Capital's profile as data
Pull Brace Pharma Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/bracepharma.com
# also
GET /v1/firms/bracepharma.com/portfolio
GET /v1/firms/bracepharma.com/coinvestors
GET /v1/firms/bracepharma.com/news